Literature DB >> 26111485

Cortical sources of resting state electroencephalographic rhythms differ in relapsing-remitting and secondary progressive multiple sclerosis.

Claudio Babiloni1, Claudio Del Percio2, Paolo Capotosto3, Giuseppe Noce4, Francesco Infarinato2, Chiara Muratori5, Christian Marcotulli6, Giovanni Bellagamba5, Elena Righi5, Andrea Soricelli7, Paolo Onorati8, Tommaso Lupattelli5.   

Abstract

OBJECTIVE: Resting state electroencephalographic (EEG) rhythms are abnormal in multiple sclerosis (MS) patients, but it is unclear if they can reflect different neurophysiologic abnormalities in MS sub-types (phenotypes) such as relapsing-remitting (RR) and secondary progressive (SP).
METHODS: We tested whether cortical sources of resting state EEG rhythms are abnormal in MS patients and differ between MS phenotypes. Resting state eyes-closed EEG activity was recorded in 36 RR, 23 SP, and 41 matched healthy subjects. EEG bands of interest were individually identified based on Transition frequency (TF), Individual alpha frequency (IAF), and Individual beta frequency (IBF). LORETA freeware estimated cortical EEG sources.
RESULTS: Widespread TF -4Hz (delta) and IAF (alpha) cortical sources were abnormal in the MS sub-groups compared to the control group. Furthermore, TF -4Hz sources in central, parietal, and limbic regions were higher in amplitude in the SP compared to the RR sub-group.
CONCLUSION: Cortical sources of resting state EEG rhythms are abnormal in MS patients at group level and differ between RR and SP sub-groups. SIGNIFICANCE: Future studies should test the utility of these EEG markers in the diagnosis and management of MS clinical phenotypes and in the therapy evaluation.
Copyright © 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Electroencephalography (EEG); Low-resolution brain electromagnetic tomography (LORETA); Multiple sclerosis (MS); Relapsing–remitting (RR); Secondary progressive (SP)

Mesh:

Year:  2015        PMID: 26111485     DOI: 10.1016/j.clinph.2015.05.029

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  7 in total

1.  Chronic demyelination-induced seizures.

Authors:  Andrew S Lapato; Jenny I Szu; Jonathan P C Hasselmann; Anna J Khalaj; Devin K Binder; Seema K Tiwari-Woodruff
Journal:  Neuroscience       Date:  2017-01-30       Impact factor: 3.590

2.  Cortical hypoactivation during resting EEG suggests central nervous system pathology in patients with chronic fatigue syndrome.

Authors:  M A Zinn; M L Zinn; I Valencia; L A Jason; J G Montoya
Journal:  Biol Psychol       Date:  2018-05-23       Impact factor: 3.251

3.  Targeting Cognitive Impairment in Multiple Sclerosis-The Road toward an Imaging-based Biomarker.

Authors:  Jeroen Van Schependom; Guy Nagels
Journal:  Front Neurosci       Date:  2017-06-30       Impact factor: 4.677

4.  Time and frequency dependent changes in resting state EEG functional connectivity following lipopolysaccharide challenge in rats.

Authors:  Matthew A Albrecht; Chloe N Vaughn; Molly A Erickson; Sarah M Clark; Leonardo H Tonelli
Journal:  PLoS One       Date:  2018-11-12       Impact factor: 3.240

5.  Central Neuropathic Pain and Profiles of Quantitative Electroencephalography in Multiple Sclerosis Patients.

Authors:  Nataliya A Krupina; Maxim V Churyukanov; Mikhail L Kukushkin; Nikolay N Yakhno
Journal:  Front Neurol       Date:  2020-01-21       Impact factor: 4.003

6.  EEG Correlates of Central Origin of Cancer-Related Fatigue.

Authors:  Didier Allexandre; Dilara Seyidova-Khoshknabi; Mellar P Davis; Vinoth K Ranganathan; Vlodek Siemionow; Declan Walsh; Guang H Yue
Journal:  Neural Plast       Date:  2020-12-11       Impact factor: 3.599

7.  Brain functional connectivity analysis in patients with relapsing-remitting multiple sclerosis: A graph theory approach of EEG resting state.

Authors:  Sepehr Shirani; Maryam Mohebbi
Journal:  Front Neurosci       Date:  2022-09-09       Impact factor: 5.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.